TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be adults ranging in age from 21-55 years old.~* Be dependent on opioids.~* Be willing to accept or desiring of opioid detoxification.~* He healthy as determined by medical screen, history, and vitals.~* Be without significant psychiatric illness besides drug dependence.~* Be without chronic pain.~* Fluent in English (speaking, writing, and reading).~* Be willing and able to participate.~Exclusion Criteria:~* Previous documented allergy to buprenorphine or morphine.~* Are dependent on other drugs besides opioids and tobacco.~* Have current history of significant use of alcohol or sedative/hypnotics.~* Have evidence of significant medical (e.g., insulin dependent diabetes mellitus) or psychiatric (e.g., schizophrenia) illness.~* Are pregnant (female volunteers will receive a pregnancy test before participation in the study and routinely during the study).~* Have an abnormal or prolongation of the corrected QT interval (QTc) on a baseline electrocardiogram (ECG).~* Are seeking treatment for their substance dependence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Morphine, then Buprenorphine (Type: EXPERIMENTAL): Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day). Participants then underwent an 18-day period of spontaneous opioid withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
- Buprenorphine, then Morphine (Type: EXPERIMENTAL): Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day). Participants then underwent an 18-day period of spontaneous withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiotherapy for Malignant Astrocytomas in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Glioblastoma and anaplastic astrocytoma, supratentorial, histologically confirmed~* Brain CT scan or MRI within 28 days before surgery~* Age: 70 years or older~* Karnofsky performance status, 70 or more.~* Life expectancy over 12 weeks~* Informed consent~Exclusion Criteria:~* Brain radiotherapy~* Chemotherapy~* Severe systemic disease

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese females~* Not pregnant at Screening and agree to use effective contraception through Month 7 of the study~* Lifetime history of 0 to 4 male or female sexual partners~* No oral temperature ≥37.5 centigrade within 24 hours prior to injection~Exclusion Criteria:~* Received a marketed HPV vaccine~* Prior abnormal Papanicolaou smear (PAP) or biopsy showing CIN~* Known history of positive test for HPV~* Known history of genital warts~* Received immune globulin or blood products within 6 months prior to first injection or plan to receive any through Month 7 of the study~* History of splenectomy, known immune disorders, or receiving immunosuppressives~* Immunocompromised or diagnosed as having human immunodeficiency virus (HIV)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- V501 (Type: EXPERIMENTAL): Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 and 45 years of age, inclusive.~* Healthy males and females with no clinically significant abnormalities.~* Body mass index ≥18.0 kg/m2 and ≤30.0 kg/m2~Exclusion Criteria:~* Sustained supine systolic blood pressure \>140 or \<100 mmHg or a diastolic blood pressure \>90 or \<60 mmHg at the Screening and Day 1 Visit.~* Abnormal ECG at Screening or Day -1 Visits indicating a second or third-degree atrioventricular block, or QRS \>110 msec, QTcF \>450 msec for males and \>470 msec for females, PR interval \>200 msec, or any rhythm other than sinus rhythm which is interpreted by the Investigator as clinically significant - History of unexplained infections or current signs of infection~* History of risk factors for Torsades de Pointes, including unexplained syncope, known Long QT Syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory assessments including hypokalemia, hypercalcemia, hypomagnesemia, or family history of Long QT Syndrome or Brugada Syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Moxifloxacin 400 mg (Type: ACTIVE_COMPARATOR): None
- TR-701 FA 1200 mg (Type: EXPERIMENTAL): None
- TR-701 FA 200 mg plus Placebo (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide written informed consent after the nature of the study has been explained and before the start of any research-related procedures.~2. Male or female between the ages of 6 and 50 years.~3. Genetically confirmed diagnosis of SMA Type 3.~4. Able to walk independently for at least 30 meters.~5. Not taking Nusinersen for the treatment of SMA (Nusinersen should be stopped at least 6 months before screening). Salbutamol is permitted only if the dose has been stable during the 6 months before screening.~6. Able to swallow oral medication.~7. Female patients of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin \[HCG\] at Screening); and must practice an effective, reliable contraceptive regimen during the study and for up to 30 days following discontinuation of treatment.~8. Ability to participate in the study based on overall health of the patient and disease prognosis, as applicable, in the opinion of the Investigator; and able to comply with all requirements of the protocol, including completion of study questionnaires.~Exclusion Criteria:~1. Epilepsy and currently on medication for epilepsy.~2. Concomitant use of medicinal products with a known potential to cause QTc prolongation.~3. Patients with long QT syndromes.~4. An electrocardiogram (ECG) within 6 months before starting treatment that shows clinically significant abnormalities, in the opinion of the Investigator.~5. Breastfeeding or pregnant at Screening or planning to become pregnant at any time during the study.~6. Treatment with an investigational drug (other than amifampridine), device, or biological agent within 6 months prior to Screening or while participating in this study.~7. Surgery for scoliosis or joint contractures within the previous 6 months.~8. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confound the assessment of the patient.~9. History of drug allergy to any pyridine-containing substances or any amifampridine excipient(s).~10. Less than a 3-point improvement in HFSME from start of the Open label Run -in period to end of Run-in (Day 0).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Amifampridine Phosphate - Placebo (Type: EXPERIMENTAL): Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
- Placebo - Amifampridine Phosphate (Type: EXPERIMENTAL): Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Singulair® add-on Study Effectiveness of Adding Montelukast to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma (0476-384)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients Is 18 Years Old~Note 1: Regulatory Requirements Necessitate The Following Criterion. It May Not Be Appropriate For Your Patients. Female Patients Of Childbearing Potential Should Be Informed Not To Become Pregnant During The Study By Using The Appropriate Contraceptive Methods (Oral Or Long-Acting Contraceptive Injections (Depo Provera), Intrauterine Device (Iud), Or Barrier Methods (E.G. Condom Or Diaphragm Plus Spermicide) Or To Be Abstinent (No Sexual Intercourse)) Beginning At Least 7 Days Before Visit 1 And Continuing At Least 14 Days After Visit 4 Or A Discontinuation Visit~Note 2: For Alberta: Investigators Who Will Recruit In Private Office, No Patients Can Be Recruited In The Study Until Approval From The College Of Physicians And Surgeons Of Alberta Ethics Committee Is Obtained~Exclusion Criteria:~* Patient Is Well Controlled, Adherent And Satisfied With Current Controller Therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Montelukast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes meeting all of the following:~* Minimum 6 month history of diabetes prior to screening visit;~* Fasting C-peptide ≥ 0.8 ng/mL at screening visit;~* HbA1C at screening visit 7-10%;~* Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose regulating drugs and supplements.~* BMI at screening visit from 25-35 kg/m2;~* LDL-C at screening ≥ 100 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 (Type: EXPERIMENTAL): ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo daily 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive.~* Participant must be taking a minimum of 400 milligrams/day (mg/day) of Levodopa (LD) equivalents and be judged by the investigator to have motor symptoms inadequately controlled by current therapy, have a recognizable/identifiable Off and On states (motor fluctuations), and have an average Off time of at least 2.5 hours/day over 3 consecutive PD Diary days with a minimum of 2 hours each day.~* Participant or caregiver, if applicable, demonstrates the understanding and correct use of the delivery system, including the insertion of the cannula into the participant's abdomen, as assessed by the investigator or designee during the Screening period.~Exclusion Criteria:~* Clinically significant, unstable medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study drug.~* History of allergic reaction or significant sensitivity to LD or constituents of the study drug (and its excipients) and/or other products in the same class.~* Participant has not received deep brain stimulation, CD/LD enteral suspension, or any other PD medication as continuous daily infusion, whether commercially available or investigational. Previous exposure to ABBV-951 is not allowed.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD) (Type: EXPERIMENTAL): After an open-label LD/CD Stabilization Period, participants will receive double-blind ABBV-951 by continuous subcutaneous infusion (CSCI) and oral placebo for LD/CD for 12 weeks
- Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951 (Type: ACTIVE_COMPARATOR): After an open-label LD/CD Stabilization Period, participants will receive double-blind oral LD/CD and CSCI of placebo for ABBV-951 for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed renal cell carcinoma with metastases~* Evidence of unidimensionally measurable disease~* Failure of 1 prior immunotherapy or no prior systemic therapy for metastatic RCC~Exclusion Criteria:~* RCC without any clear (conventional) cell component~* History of or known brain metastases~* Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib + Gefitinib (Type: EXPERIMENTAL): Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib~Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed CF diagnosis by two positive chloride sweat tests or gene analysis~* Confirmed PEI by historical CFA \< 70% without supplementation or current or historical fecal elastase \< 50µg/g stool (within the last 12 months)~* Subjects of 12 years or older~* Currently receiving treatment with a commercially available pancreatic enzyme product on a stable dose for more than 3 months~* Clinically stable condition without evidence of acute respiratory disease or any other acute condition~* Females of child-bearing potential must agree to continue using a medically acceptable method of birth control~Exclusion Criteria:~* Ileus or acute abdomen~* History of fibrosing colonopathy~* History of distal ileal obstruction syndrome within 6 months of enrollment~* Use of an immunosuppressive drug~* Any type of malignancy involving the digestive tract in the last 5 years~* Known infection with HIV

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam to Prevent Post-Traumatic Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute head injury associated with one of the following:~Intracranial hemorrhage, including epidural, subdural and intracerebral hemorrhage or with cerebral contusion(s) of any size; Penetrating (foreign body) head injury; Skull fracture and dural tear; Seizure within 8 hours of head injury~* Onset of head injury within 8-hours of proposed treatment initiation.~* Glasgow Coma Scale 6-15.~Exclusion Criteria:~* Clinical contraindications:~  * Previous epilepsy or status epilepticus.~ * Any systemic illness or unstable medical condition that might pose additional risk, including: renal insufficiency, other unstable metabolic or endocrine disturbances, and active systemic cancer.~ * Psychosis within six months of enrollment as determined by history of hospitalization for psychosis or medications for psychosis.~ * Moderate to severe mental retardation (IQ\< 55 or\>2 school grade levels below the expected for age \[expected age = grade level +5\]).~* Clinical/Laboratory Indicators:~  * Serum creatinine \> 1.5 on the day of treatment initiation for adults.~ * Serum creatinine ≥1.5 for subjects ≥17 years old, ≥1.0 for subjects 13-17 years old and ≥0.7 for subjects 6-12 years old.~ * Pregnancy~ * Use of any CNS-active investigational drugs within 3 months of enrollment.~ * Use of Antiepileptic Drugs (AEDs) within two months of enrollment, for any indication.~ * Allergy/sensitivity to study drugs or their formulations:~ * Active drug or alcohol dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements:~ * Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: ACTIVE_COMPARATOR): 66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
- No Intervention Control (Type: NO_INTERVENTION): 60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete